76429-73-7

Usage

Chemical Properties

White powder

InChI:InChI=1/C9H8O3/c10-9(11)7-1-2-8-6(5-7)3-4-12-8/h1-2,5H,3-4H2,(H,10,11)

Upstream product

• 496-16-2 2.3-dihydrobenzofuran 
• 615-58-7 2,4-dibromophenol 
• 124-38-9 carbon dioxide 
• 76429-66-8 β-(2,4-Dibromophenoxy)ethyl Bromide 
• 90843-31-5 1-(2,3-dihydrobenzofuran-5-yl)ethanone 

Downstream Products

• 1599432-03-7 (E)-1-(4-(2,3-dihydrobenzofuran-5-carbonyl)piperazin-1-yl)-3-(4-methoxyphenyl)prop-2-en-1-one 
• 55745-70-5 2,3-dihydro-benzofuran-5-carbaldehyde 
• 55745-71-6 2,3-dihydrobenzofuran-5-carbonyl chloride 
• 321195-99-7 2,3-dihydro-1-benzofuran-5-carbohydrazide 
• 103262-35-7 (2,3-dihydrobenzo[b]furan-5-yl)methanol 
• 588702-80-1 methyl 2,3-dihydro-1-benzofuran-5-carboxylate 
• 1398583-44-2 3-({(2,3-dihydro-1-benzofuran-5-ylcarbonyl)[1-(4-fluorophenyl)ethyl]amino}methyl)benzoic acid 
• 1186388-70-4 C₂₀H₁₉N₃O₂S 
• 198554-17-5 4-[1-(2,3-dihydro-1-benzofuran-5-ylcarbonyl)piperidin-4-yl]-6-(4-methoxybenzyl)pyrimidin-2-amine 
• 108763-47-9 5-(methoxycarbonyl)benzo[b]furan 
• 90721-27-0 benzofuran-5-carboxylic acid 

Relevant academic research and scientific papers

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5- carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: Synthesis and structure-activity relationship

N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the α7 neuronal nicotinic acetylcholine receptor (α7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective a7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.

COMPOUNDS HAVING BOTH α7 NICOTINIC AGONIST ACTIVITY AND 5HT3 ANTAGONIST ACTIVITY FOR TREATMENT OF CNS DISEASES

The invention discloses compounds that are selective α7 nAChR agonists and 5-HT3 antagonists. The compounds are useful for treating many CNS diseases.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is 2These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.

Oxygen Heterocycles by the Parham Cyclialkylation

The addition of butyllithium at -100 deg C to ω-bromoalkyl ethers of o-bromophenol (and its congeners) led to preferential exchange of the aryl bromine at position 2.The resulting organolithium reagents, under suitable conditions, cyclized to afford 2,3-dihydrobenzofurans (6), 3,4-dihydro-2H-1-benzopyrans (13), or 2,3,4,5-tetrahydro-1-benzoxepins (16) in good yields, but less satisfactory results were obtained with the intermediate expected to produce 8-methyl-3,4,5,6-tetrahydro-2H-1-benzoxocin (19). ω-Bromoethyl and ω-bromopropyl ethers of suitable dibromophenols were treated successively with 2 equiv of butyllithium and an electrophile to yield derivatives of 6 and 13.